• Je něco špatně v tomto záznamu ?

Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin

H. Nakamura, E. Koziolová, P. Chytil, K. Tsukigawa, J. Fang, M. Haratake, K. Ulbrich, T. Etrych, H. Maeda,

. 2016 ; 13 (12) : 4106-4115. [pub] 20161121

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016876

Many conjugates of water-soluble polymers with biologically active molecules were developed during the last two decades. Although, therapeutic effects of these conjugates are affected by the properties of carriers, the properties of the attached drugs appear more important than the same carrier polymer in this case. Pirarubicin (THP), a tetrahydropyranyl derivative of doxorubicin (DOX), demonstrated more rapid cellular internalization and potent cytotoxicity than DOX. Here, we conjugated the THP or DOX to N-(2-hydroxypropyl)methacrylamide copolymer via a hydrazone bond. The polymeric prodrug conjugates, P-THP and P-DOX, respectively, had comparable hydrodynamic sizes and drug loading. Compared with P-DOX, P-THP showed approximately 10 times greater cellular uptake during a 240 min incubation and a cytotoxicity that was more than 10 times higher during a 72-h incubation. A marginal difference was seen in P-THP and P-DOX accumulation in the liver and kidney at 6 h after drug administration, but no significant difference occurred in the tumor drug concentration during 6-24 h after drug administration. Antitumor activity against xenograft human pancreatic tumor (SUIT2) in mice was greater for P-THP than for P-DOX. To sum up, the present study compared the biological behavior of two different drugs, each attached to an N-(2-hydroxypropyl)methacrylamide copolymer carrier, with regard to their uptake by tumor cells, body distribution, accumulation in tumors, cytotoxicity, and antitumor activity in vitro and in vivo. No differences in the tumor cell uptake of the polymer-drug conjugates, P-THP and P-DOX, were observed. In contrast, the intracellular uptake of free THP liberated from the P-THP was 25-30 times higher than that of DOX liberated from P-DOX. This finding indicates that proper selection of the carrier, and especially conjugated active pharmaceutical ingredient (API) are most critical for anticancer activity of the polymer-drug conjugates. THP, in this respect, was found to be a more preferable API for polymer conjugation than DOX. Hence the treatment based on enhanced permeability and retention (EPR) effect that targets more selectively to solid tumors can be best achieved with THP, although both polymer conjugates of DOX and THP exhibited the EPR effects and drug release profiles in acidic pH similarly.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016876
003      
CZ-PrNML
005      
20180515103432.0
007      
ta
008      
180515s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.molpharmaceut.6b00697 $2 doi
035    __
$a (PubMed)27934482
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Nakamura, Hideaki $u Research Institute for Drug Delivery Science, Sojo University , Ikeda 4-22-1, Nishi-ku, Kumamoto 860-0082, Japan. Faculty of Pharmaceutical Sciences, Sojo University , Ikeda 4-22-1, Nishi-ku, Kumamoto 860-0082, Japan.
245    10
$a Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin / $c H. Nakamura, E. Koziolová, P. Chytil, K. Tsukigawa, J. Fang, M. Haratake, K. Ulbrich, T. Etrych, H. Maeda,
520    9_
$a Many conjugates of water-soluble polymers with biologically active molecules were developed during the last two decades. Although, therapeutic effects of these conjugates are affected by the properties of carriers, the properties of the attached drugs appear more important than the same carrier polymer in this case. Pirarubicin (THP), a tetrahydropyranyl derivative of doxorubicin (DOX), demonstrated more rapid cellular internalization and potent cytotoxicity than DOX. Here, we conjugated the THP or DOX to N-(2-hydroxypropyl)methacrylamide copolymer via a hydrazone bond. The polymeric prodrug conjugates, P-THP and P-DOX, respectively, had comparable hydrodynamic sizes and drug loading. Compared with P-DOX, P-THP showed approximately 10 times greater cellular uptake during a 240 min incubation and a cytotoxicity that was more than 10 times higher during a 72-h incubation. A marginal difference was seen in P-THP and P-DOX accumulation in the liver and kidney at 6 h after drug administration, but no significant difference occurred in the tumor drug concentration during 6-24 h after drug administration. Antitumor activity against xenograft human pancreatic tumor (SUIT2) in mice was greater for P-THP than for P-DOX. To sum up, the present study compared the biological behavior of two different drugs, each attached to an N-(2-hydroxypropyl)methacrylamide copolymer carrier, with regard to their uptake by tumor cells, body distribution, accumulation in tumors, cytotoxicity, and antitumor activity in vitro and in vivo. No differences in the tumor cell uptake of the polymer-drug conjugates, P-THP and P-DOX, were observed. In contrast, the intracellular uptake of free THP liberated from the P-THP was 25-30 times higher than that of DOX liberated from P-DOX. This finding indicates that proper selection of the carrier, and especially conjugated active pharmaceutical ingredient (API) are most critical for anticancer activity of the polymer-drug conjugates. THP, in this respect, was found to be a more preferable API for polymer conjugation than DOX. Hence the treatment based on enhanced permeability and retention (EPR) effect that targets more selectively to solid tumors can be best achieved with THP, although both polymer conjugates of DOX and THP exhibited the EPR effects and drug release profiles in acidic pH similarly.
650    _2
$a akrylamidy $x chemie $7 D000178
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorová antibiotika $x chemie $x farmakologie $7 D000903
650    _2
$a protinádorové látky $x chemie $x farmakologie $7 D000970
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a doxorubicin $x analogy a deriváty $x chemie $x farmakologie $7 D004317
650    _2
$a nosiče léků $x aplikace a dávkování $x chemie $7 D004337
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední BALB C $7 D008807
650    _2
$a polymery $x aplikace a dávkování $x chemie $7 D011108
650    _2
$a experimentální sarkom $x farmakoterapie $x metabolismus $x patologie $7 D012513
650    _2
$a nádorové buňky kultivované $7 D014407
650    _2
$a xenogenní modely - testy protinádorové aktivity $7 D023041
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Koziolová, Eva $u Institute of Macromolecular Chemistry, The Czech Academy of Sciences , Heyrovsky Sq. 2, 162 06 Prague 6, Czech Republic.
700    1_
$a Chytil, Petr $u Institute of Macromolecular Chemistry, The Czech Academy of Sciences , Heyrovsky Sq. 2, 162 06 Prague 6, Czech Republic.
700    1_
$a Tsukigawa, Kenji $u Faculty of Pharmaceutical Sciences, Sojo University , Ikeda 4-22-1, Nishi-ku, Kumamoto 860-0082, Japan.
700    1_
$a Fang, Jun $u Research Institute for Drug Delivery Science, Sojo University , Ikeda 4-22-1, Nishi-ku, Kumamoto 860-0082, Japan. Faculty of Pharmaceutical Sciences, Sojo University , Ikeda 4-22-1, Nishi-ku, Kumamoto 860-0082, Japan.
700    1_
$a Haratake, Mamoru $u Faculty of Pharmaceutical Sciences, Sojo University , Ikeda 4-22-1, Nishi-ku, Kumamoto 860-0082, Japan.
700    1_
$a Ulbrich, Karel $u Institute of Macromolecular Chemistry, The Czech Academy of Sciences , Heyrovsky Sq. 2, 162 06 Prague 6, Czech Republic.
700    1_
$a Etrych, Tomáš $u Institute of Macromolecular Chemistry, The Czech Academy of Sciences , Heyrovsky Sq. 2, 162 06 Prague 6, Czech Republic.
700    1_
$a Maeda, Hiroshi $u Research Institute for Drug Delivery Science, Sojo University , Ikeda 4-22-1, Nishi-ku, Kumamoto 860-0082, Japan.
773    0_
$w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 13, č. 12 (2016), s. 4106-4115
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27934482 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180515103606 $b ABA008
999    __
$a ok $b bmc $g 1300500 $s 1013716
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 13 $c 12 $d 4106-4115 $e 20161121 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...